SecBot SecBot
8-K ·Filed Feb 26, 2026

VERA

Vera Therapeutics, Inc.
MIXED
Impact 7/10
Horizonmonths Processed8mo ago SEC0001193125-26-073421
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The positive clinical data and FDA priority review are significant catalysts for Vera Therapeutics, indicating potential for a major commercial launch in mid-2026. However, the substantial increase in net loss and operating expenses signals high ongoing costs. Traders should monitor the company's cash burn rate and upcoming clinical milestones, as the stock may react strongly to the PDUFA decision in July 2026.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$42.35
T+0 close · Feb 26, 2026 · via day close
Latest settled
−18.89%
T+60 · $34.35
Vs SPY
−26.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $42.35entry
  2. T+1 · 9mo ago −3.68%α −3.23% · $40.79
  3. T+5 · 9mo ago −8.26%α −7.14% · $38.85
  4. T+20 · 8mo ago −4.94%α +1.47% · $40.26
  5. T+60 · 6mo ago −18.89%α −26.64% · $34.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics reported strong business progress with positive Phase 3 data for atacicept in IgA nephropathy, FDA priority review granted with a PDUFA date of July 7, 2026, and a robust balance sheet from $800 million in financings. However, the company reported a significant net loss increase to $299.6 million in 2025 from $152.1 million in 2024, driven by higher R&D and G&A expenses.

Key Financial Metrics

EPS
$-4.66

Key Facts

  • Positive Phase 3 data from the ORIGIN 3 study of atacicept in IgA nephropathy presented at ASN Kidney Week and published in NEJM
  • FDA granted priority review to the Biologics License Application (BLA) for atacicept with a PDUFA date of July 7, 2026
  • Equity and debt financings in 2025 raised $800 million in gross proceeds, strengthening the balance sheet
  • Cash, cash equivalents, and marketable securities totaled $714.6 million as of December 31, 2025
  • Net loss increased to $299.6 million in 2025 from $152.1 million in 2024, with net loss per diluted share rising to $4.66 from $2.75
  • Net cash used in operating activities increased to $241.1 million in 2025 from $134.7 million in 2024
  • Research and development expenses increased to $215.3 million in 2025 from $126.2 million in 2024

Financial Impact

Net loss increased by 97% YoY to $299.6 million; R&D expenses increased by 71% YoY; $800 million in gross proceeds from financings

revenueepscashFlowdebt

Risk Factors

  • High and increasing net losses could pressure the balance sheet despite recent financings
  • The company remains pre-revenue with no commercial products, making it highly dependent on the success of atacicept
  • Clinical trial results may not lead to regulatory approval or commercial success
  • Market volatility due to insider selling activity, with 7 insider sells totaling $1.4 million in the last 30 days

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073421
Document: vera-20260226.htm0001193125-26-073421
Document: 0001193125-26-073421-index-headers.html0001193125-26-073421
Document: 0001193125-26-073421-index.html0001193125-26-073421
Document: 0001193125-26-073421.txt0001193125-26-073421

Track record

25 reports on VERA

Performance horizon

13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens in 8h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026